We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+32.81%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$123M
AUM Growth
+$23M
Cap. Flow
-$4.05M
Cap. Flow %
-3.28%
Top 10 Hldgs %
69.68%
Holding
33
New
6
Increased
7
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.13M
2
EVH icon
Evolent Health
EVH
+$3.4M
3
EXAS
Exact Sciences
EXAS
+$2.73M
4
MDRX
Veradigm Inc. Common Stock
MDRX
+$2.67M
5
GHDX
Genomic Health, Inc.
GHDX
+$2.51M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$3.98M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.62M
3
BLUE
bluebird bio
BLUE
+$3.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.36M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$1.71M

Sector Composition

Rank Sector Weight
1 Healthcare 82.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
26
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$694K 0.56%
5,000
– –
BMY icon
27
Bristol-Myers Squibb
BMY
$134B
– –
-21,000
Closed -$1.54M
DXCM icon
28
DexCom
DXCM
$32.9B
– –
-60,000
Closed -$1.19M
DXCM icon
29
PUT
DexCom
DXCM
$32.9B
– –
-60,000
Closed -$1.19M
SAGE
30
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-65,000
Closed -$1.96M
XBI icon
31
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
– –
-30,000
Closed -$1.62M
TSRO
32
DELISTED
TESARO, Inc.
TSRO
– –
-20,000
Closed -$1.68M
AVXS
33
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-45,000
Closed -$1.71M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Casdin Capital held 33 positions worth $123M, up 23% from $100M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Casdin Capital withdrew a net $4.05M in Q3 2016, closing 7 positions and reducing 12 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $1.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 80% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Exact Sciences worth $2.88M.

  • Casdin Capital's largest Q3 2016 buy was Exact Sciences: 155,000 shares worth $2.88M.
  • Casdin Capital added most to Agios Pharmaceuticals in Q3 2016, an estimated $4.13M increase.
  • Casdin Capital's biggest Q3 2016 reduction was Spark Therapeutics, Inc. Common Stock, cutting an estimated $3.98M.
  • Casdin Capital fully exited AveXis, Inc. Common Stock in Q3 2016, selling an estimated $1.71M.
  • Casdin Capital's ten largest holdings make up 70% of its $123M portfolio in Q3 2016.
  • Casdin Capital opened 6 new positions and closed 7 in Q3 2016.
  • Casdin Capital's portfolio value rose 23% quarter-over-quarter to $123M.

Based on Casdin Capital's 13F filing for Q3 2016, filed 14 Nov 2016.